Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Heart valve – Specific material for heart valve
Reexamination Certificate
2000-02-16
2003-12-23
McDermott, Corrine (Department: 3738)
Prosthesis (i.e., artificial body members), parts thereof, or ai
Heart valve
Specific material for heart valve
C623S002120
Reexamination Certificate
active
06666886
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention pertains generally to substitute heart valves, and more particularly to tissue-engineered cardiovascular valves.
BACKGROUND
The introduction of substitute heart valves (SHV's) into clinical practice in the 1960's resulted in a dramatic improvement in the longevity and symptomatology of patients with valvular heart disease. However, major problems remain. With the exception of autograft and allograft aortic valves and repaired mitral valves, the 10-year mortality after valve replacement with either mechanical or bioprosthetic valve ranges between 30 and 55 percent. The incidence of thromboembolic complications is 1.5-3.0 per 100 patient-years (percent/year); prosthetic valve endocarditis averages approximately 0.5 percent/year. The incidence of bleeding complications is 1.5-3.0 percent/year for anticoagulated patients and approximately one-third that rate for patients who are not anticoagulated. The reoperation rate ranges between 2 and 4 percent/year; by 10 years one-third of bioprosthetic valves require replacement and by 15 years more than two-thirds do. Autografts and allograft aortic valve substitutes have limited availability and require longer and more complicated surgery; therefore, these valve substitutes are prescribed for younger patients, generally below age 60. Mitral valve repair is helpful in approximately two-thirds of patients, but often is less suitable for older patients and decreases but does not eliminate the morbidity of bioprosthetic valves. These data loudly announce and convincingly certify that SHV's developed and approved for clinical use 15-30 years ago replace one disease with another and are far from ideal.
Better SHV's that can be quickly and safely implanted in older patients who often have comorbid disease are needed. Incremental improvements in existing mechanical and bioprosthetic heart valves may help, but visionary new designs and new approaches that specifically address the complications of reduced lifespan, thromboembolism, the need for anticoagulation, endocarditis and structural deterioration are more appropriate goals for our biotechnical effort. New biomaterials and surface coatings, new mechanical valve designs, longer lasting hemodynamically normal xenografts and tissue-engineered valves from autologous cells are some of the new ideas for developing an ideal heart valve substitute.
Development of truly new SHV's requires a multidisciplinary approach, spanning clinical science, cell and molecular biology, materials science and bioengineering. Although much is known regarding the mechanisms of thromboembolism, endocarditis, structural deterioration and other morbid events, much more basic information is needed before a SHV becomes a “cure.”
Thus, while mechanical and bioprosthetic heart valves (mhv and bhv) have made a dramatic impact since their introduction in the 1960's, the 10-year mortality after replacement is relatively high, with undesirable reoperation rates because of mechanical failure (mhv), bleeding and thromboembolic complications (mhv and bhv), and calcification (bhv). Autografts and allografts, while more successful, fall far short in supply. The need is particularly great for juveniles since neither mhv nor bhv have the capacity to grow. Thus, there is great interest in developing a new generation of substitute heart valves based on tissue-engineering approaches (1).
SUMMARY OF THE INVENTION
We have developed a mold to fabricate multileaflet “valve-equivalents” based on the tissue-equivalent approach of entrapping tissue cells in a self-assembled biopolymer scaffold. The mold design results in leaflet structures possessing circumferential alignment of protein fibers characteristic of native leaflets. Accordingly, the present invention provides method and apparatus for forming one or more substitute valve leaflets from a solution of fibrillar biopolymer gel and tissue cells, wherein there is provided a female surface and a male surface adapted to cooperate with the female surface to define a compaction volume therebetween for receiving the solution, wherein the method and apparatus is adapted to produce one or more contiguous substitute valve leaflets having structural alignment and mechanical properties which mimic those of natural valve leaflets.
REFERENCES:
patent: 5558875 (1996-09-01), Wang
patent: 5759830 (1998-06-01), Vacanti et al.
patent: 5770417 (1998-06-01), Vacanti et al.
patent: 5855601 (1999-01-01), Bessler et al.
patent: 5899937 (1999-05-01), Goldstein et al.
patent: 5910170 (1999-06-01), Reimink et al.
patent: 5948654 (1999-09-01), Tranquillo et al.
patent: 5994123 (1999-11-01), Olszewski et al.
patent: 6146892 (2000-11-01), Ma et al.
Barocas, V.H., et al., “An Anistrophic Biphasic Theory of Tissue-Equivalent Mechanics: The Interplay Among Cell Traction, Fibrillar Network Deformation, Fibril Alignment, and Cell Contact Guidance”,Journal of Biomechanical Engineering, 119, pp. 137-145, (May 1997).
Barocas, V.H., et al., “Engineered Alignment in Media Equivalents: Magnetic Prealignment and Mandreal Compaction”,Journal of Biomechanical Engineering, 120, pp. 660-666, (Oct. 1998).
Christie, G.W., “Anatomy of Aortic Heart Valve Leaflets: The Influence of Glutaraldehyde Fixation on Function”,European Journal of Cardio-thoracic Surgery, 6(12),Suppl. 1, pp. S 25-S33, (1992).
Girton, T.S., et al., “Exploiting Glycation to Stiffen and Strengthen Tissue Equivalents for Tissue Engineering”, pp. 87-92, (May 5, 1999), http://www3.interscience.wiley.com/cgi-bin/issuetoc?ID=61004825.
Gottlob, R., et al.,Venous Valves, Springer-Verlag, Wein, pp. 1-227, (1986).
L'Heureux, N., et al., “In Vitro Construction of a Human Blood Vessel from Cultured Vascular Cells: A Morphologic Study”,Journal of Vascular Surgery, 17(3), pp. 499-509, (Mar. 1999).
Sapatnekar, S., et al., “Blood-biomaterial interaction in a flow system in the presence of bacteria: Effect of protein adsorption”,Journal of Biomedical Materials Research, 29, pp. 247-256, (1995).
Sauren, A.H., et al., “Aortic Valve Histology and its Relation with Mechanics-Preliminary Report”,Journal of Biomechanics, 13(2), pp. 97-104, (1980).
Sauren, A.H., et al., “The Mechanical Properties of Porcine Aortic Valve Tissues”,Journal of Biomechanics, 16(5), pp. 327-337, (1983).
Shinoka, T., et al., “Tissue Engineering Heart Valves: Valve Leaflet Replacement Study in a Lamb Model”,Supplement to The Annals of Thoracic Surgery, 60(6)Suppl., pp. S513-S516, (Dec. 1995).
Talman, E.A., et al., “Internal Shear Properties of Fresh Porcine Aortic Valve Cusps: Implications for Normal Valve Function”,J. Heart Valve Dis., 5(2), pp. 152-159, (1996).
Girton Timothy S.
Neidert Michael
Tranquillo Robert T.
Barrett Thomas
McDermott Corrine
Regents of the University of Minnesota
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Tissue equivalent approach to a tissue-engineered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue equivalent approach to a tissue-engineered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue equivalent approach to a tissue-engineered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3134771